Related Experiment Videos
M2000: a revolution in pharmacology
Abbas Mirshafiey1, Salvatore Cuzzocrea, Bernd H A Rehm
1Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. a_mirshafiey@yahoo.com
Summary
M2000, a novel non-steroidal anti-inflammatory drug (NSAID), effectively reduces inflammation and immunosuppression in various disease models. It demonstrates significant therapeutic effects on kidney diseases and exhibits superior safety compared to existing treatments.
Area of Science:
- Pharmacology
- Immunology
- Nephrology
Background:
- A novel non-steroidal anti-inflammatory drug (NSAID), M2000 (beta-D-mannuronic acid), was developed.
- Its anti-inflammatory and immunosuppressive properties required investigation.
Purpose of the Study:
- To evaluate the tolerability, anti-inflammatory, and immunosuppressive effects of M2000.
- To assess its therapeutic potential in models of rheumatoid arthritis, multiple sclerosis, and kidney diseases.
- To determine the biocompatibility and pharmacotoxicology profile of M2000.
Main Methods:
- M2000's efficacy was tested in experimental autoimmune arthritis (AIA), experimental autoimmune encephalomyelitis (EAE), immune complex glomerulonephritis (ICG), and experimental nephrosis models.
- Biocompatibility and pharmacotoxicology were assessed using cell lines, zymography, and serum/urine markers.
- Drug effects on paw edema, clinical signs, histological parameters, proteinuria, BUN, creatinine, cholesterol, and MMP-2 activity were measured.
Main Results:
- M2000 significantly reduced inflammation and histopathological damage in AIA and EAE models.
- It demonstrated immunosuppressive efficacy, diminishing clinical signs and histological damage in EAE, confirmed by lymph node cell proliferation assays.
- M2000 treatment led to significant reductions in proteinuria, BUN, serum creatinine, cholesterol, and glomerular lesions in kidney disease models.
- The drug inhibited MMP-2 activity and showed a superior safety profile compared to dexamethasone and conventional NSAIDs, with no ulcerogenic effects.
Conclusions:
- M2000 is a novel NSAID with low molecular weight and demonstrated therapeutic benefits in glomerulonephritis and nephrosis.
- It exhibits significant anti-inflammatory and immunosuppressive properties with a favorable safety profile, lacking gastro-nephrotoxicity.
- M2000 is recommended as a safe and effective option for managing inflammatory conditions.